Table 1.
Characteristic | NAC + IMRT [cases (%)] | CCRT + AC [cases (%)] | χ2 | P |
---|---|---|---|---|
Total | 117 | 123 | ||
Age (years) | 0.199 | 0.656 | ||
<50 | 83 (70.9) | 84 (68.3) | ||
≥50 | 34 (29.1) | 39 (31.7) | ||
Gender | 1.148 | 0.284 | ||
Male | 89 (76.1) | 86 (69.9) | ||
Female | 28 (23.9) | 37 (30.1) | ||
T stage | 1.029 | 0.794 | ||
T1 | 4 (3.4) | 4 (3.3) | ||
T2 | 11 (9.4) | 14 (11.4) | ||
T3 | 57 (48.7) | 65 (52.8) | ||
T4 | 45 (38.5) | 40 (32.5) | ||
N stage | 3.578 | 0.311 | ||
N0 | 22 (18.8) | 27 (22.0) | ||
N1 | 40 (34.2) | 50 (40.6) | ||
N2 | 46 (39.3) | 42 (34.1) | ||
N3 | 9 (7.7) | 4 (3.3) | ||
Clinical stage | 2.256 | 0.133 | ||
III | 65 (55.6) | 80 (65.0) | ||
IV | 52 (44.4) | 43 (35.0) | ||
WHO histology | 0.313 | 0.576 | ||
II | 13 (11.1) | 11 (8.9) | ||
III | 104 (88.9) | 112 (91.1) |
NAC neoadjuvant chemotherapy, IMRT intensity-modulated radiotherapy, CCRT concurrent chemoradiotherapy, AC adjuvant chemotherapy, WHO World Health Organization